This invention provides cholesterol absorption inhibitors of Formula I:
and the pharmaceutically acceptable salts thereof, wherein R
12
is an alkyl, alkeny or alkynyl group mono- or poly-substituted with —OH, —COOH or a combination of —OH and —COOH, and R
9
contains an alkyl, alkeny or alkynyl group substituted with a heterocyclic ring, amino or sulfonyl. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating atherosclerosis and preventing atherosclerotic disease events.
Anti‐migration of Nitrogen‐rich N‐Heterocyclic Ferrocenes and Their Combustion Catalytic Properties in the Thermal Decomposition of Energetic Oxidizers
highly thermal stable. Cyclic voltammetry results implied that some new ferrocenyl compounds exhibit reversible electrochemical behavior, which are favorable for their combustion catalytic performance in the composite solid propellants. The anti-migration tests confirmed that the new ferrocenyl compounds exhibit neglectable migration trends after four-week aging on comparison with ferrocene and catocene
metal complexes indicate that metal‐mediated basepairs of TriPyr may not be fully planar. An investigation of DNA oligonucleotide duplexes comprising the new “click” nucleosides showed that they can bind AgI to form metal‐mediated basepairs. In particular the mispair formed from TriPy and the previously established imidazole nucleoside is significantly stabilized in the presence of AgI. A comparison
This invention provides cholesterol absorption inhibitors of Formula I: and the pharmaceutically acceptable salts thereof, wherein R
12
is a hydroxylated alkyl group and R
9
contains a heterocyclic ring. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating atherosclerosis and preventing atherosclerotic disease events.